Yuecheng Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuecheng Yang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Jun Zhang
Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China
6 shared publications Yunkui Zhang
Affiliations Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
4 shared publicationsCongxia Pan
Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
2 shared publicationsGuoxia Zhou
Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
2 shared publicationsHuanyu Luo
Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
2 shared publications- Xing Wu
Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 4349-4359
Esketamine as an Epidural Adjuvant for Postoperative Analgesia in Gynecological Malignancy Surgery: A Randomized Trial
Objective: This study aims to evaluate the efficacy of esketamine as an epidural adjuvant in mitigating postoperative pain, particularly following the discontinuation of epidural analgesia in patients undergoing open surgery for gynecological malignancies. Design: A randomized controlled trial. Methods: Eighty-eight patients were randomized to receive either esketamine (0.4 mg/kg) combined with sufentanil and ropivacaine (eskatamine group) or sufentanil and ropivacaine alone (control group) via patient-controlled epidural analgesia. Primary outcomes included pain scores on postoperative day 3, assessed using the numeric rating scale. Secondary outcomes included pain scores on postoperative days 1 to 4, Quality of Recovery-15 scores, rescue analgesic requirements, and adverse events. Results: The eskatamine group demonstrated a significant reduction in nocturnal pain intensity on postoperative day 2 compared with controls (median 3.0 vs 4.0, P = 0.044), with fewer patients requiring rescue analgesics on postoperative day 3 (13.4% vs 32.6%, P = 0.036). However, no significant differences were observed in rest pain, movement pain, or breakthrough pain across postoperative day 1– 4. Subgroup analysis revealed higher Recovery-15 scores for moderate pain in the esketamine group (median 10 vs 9, P = 0.048). Transient dizziness was more frequent in the esketamine group (47.7% vs 23.3%, P = 0.017), but no persistent adverse effects were observed. Conclusion: Esketamine, as an adjuvant in patient-controlled epidural analgesia, reduced nocturnal pain on postoperative day 2, shorten the moderate pain duration and lower rescue analgesics within 24 hours after the removal of analgesia device. However, it did not affect pain scores although less rescue analgesia was needed on postoperative day 3.
- 1 August 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 4349-4359
Open AccessEsketamine as an Epidural Adjuvant for Postoperative Analgesia in Gynecological Malignancy Surgery: A Randomized Trial
Objective: This study aims to evaluate the efficacy of esketamine as an epidural adjuvant in mitigating postoperative pain, particularly following the discontinuation of epidural analgesia in patients undergoing open surgery for gynecological malignancies. Design: A randomized controlled trial. Methods: Eighty-eight patients were randomized to receive either esketamine (0.4 mg/kg) combined with sufentanil and ropivacaine (eskatamine group) or sufentanil and ropivacaine alone (control group) via patient-controlled epidural analgesia. Primary outcomes included pain scores on postoperative day 3, assessed using the numeric rating scale. Secondary outcomes included pain scores on postoperative days 1 to 4, Quality of Recovery-15 scores, rescue analgesic requirements, and adverse events. Results: The eskatamine group demonstrated a significant reduction in nocturnal pain intensity on postoperative day 2 compared with controls (median 3.0 vs 4.0, P = 0.044), with fewer patients requiring rescue analgesics on postoperative day 3 (13.4% vs 32.6%, P = 0.036). However, no significant differences were observed in rest pain, movement pain, or breakthrough pain across postoperative day 1– 4. Subgroup analysis revealed higher Recovery-15 scores for moderate pain in the esketamine group (median 10 vs 9, P = 0.048). Transient dizziness was more frequent in the esketamine group (47.7% vs 23.3%, P = 0.017), but no persistent adverse effects were observed. Conclusion: Esketamine, as an adjuvant in patient-controlled epidural analgesia, reduced nocturnal pain on postoperative day 2, shorten the moderate pain duration and lower rescue analgesics within 24 hours after the removal of analgesia device. However, it did not affect pain scores although less rescue analgesia was needed on postoperative day 3.
- Open Access
Association between dexmedetomidine sedation and mortality in critically ill patients with ischaemic stroke: a retrospective study based on MIMIC-IV database
Objective This study investigates the effects of dexmedetomidine on short-term and long-term survival rates in intensive care unit (ICU) patients with ischaemic stroke. Design This is a retrospective study. Setting Data were sourced from the Medical Information Mart for Intensive Care IV database. Participants This study analysed 2816 patients with ischaemic stroke from the US Intensive Care database. Interventions Dexmedetomidine administration during the ICU stay was defined as the exposure. Methods Patients were categorised into the dexmedetomidine group and the control group. Cox regression analysis was used to identify factors that may influence the 28-day mortality rate of patients with ischaemic stroke. High-risk factors were incorporated as covariates, and a 1:1 propensity score matching using the logit model was constructed to compare the prognosis between the two groups. Primary and secondary outcome measures The primary outcome was 28-day mortality. The secondary outcomes included in-hospital mortality, ICU length of stay, hospital length of stay, mechanical ventilation duration and 180-day mortality in discharged patients. Results A total of 2816 patients were included. Cox regression analysis revealed that dexmedetomidine use was associated with a reduced risk of 28-day mortality. Following propensity score matching, each group comprised 407 patients. Dexmedetomidine was found to improve 28-day mortality (27.8% vs 36.6%, p=0.007). However, it was also associated with the prolonged length of hospital and ICU stay (p=0.002). Among discharged patients, dexmedetomidine use was also associated with an improved 180-day mortality rate (p=0.0019). Conclusion The use of dexmedetomidine is associated with improved short-term and long-term prognosis in patients with ischaemic stroke and could potentially confer benefits in those receiving mechanical ventilation.
Open AccessAssociation between dexmedetomidine sedation and mortality in critically ill patients with ischaemic stroke: a retrospective study based on MIMIC-IV database
Objective This study investigates the effects of dexmedetomidine on short-term and long-term survival rates in intensive care unit (ICU) patients with ischaemic stroke. Design This is a retrospective study. Setting Data were sourced from the Medical Information Mart for Intensive Care IV database. Participants This study analysed 2816 patients with ischaemic stroke from the US Intensive Care database. Interventions Dexmedetomidine administration during the ICU stay was defined as the exposure. Methods Patients were categorised into the dexmedetomidine group and the control group. Cox regression analysis was used to identify factors that may influence the 28-day mortality rate of patients with ischaemic stroke. High-risk factors were incorporated as covariates, and a 1:1 propensity score matching using the logit model was constructed to compare the prognosis between the two groups. Primary and secondary outcome measures The primary outcome was 28-day mortality. The secondary outcomes included in-hospital mortality, ICU length of stay, hospital length of stay, mechanical ventilation duration and 180-day mortality in discharged patients. Results A total of 2816 patients were included. Cox regression analysis revealed that dexmedetomidine use was associated with a reduced risk of 28-day mortality. Following propensity score matching, each group comprised 407 patients. Dexmedetomidine was found to improve 28-day mortality (27.8% vs 36.6%, p=0.007). However, it was also associated with the prolonged length of hospital and ICU stay (p=0.002). Among discharged patients, dexmedetomidine use was also associated with an improved 180-day mortality rate (p=0.0019). Conclusion The use of dexmedetomidine is associated with improved short-term and long-term prognosis in patients with ischaemic stroke and could potentially confer benefits in those receiving mechanical ventilation.
- Open Access
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320047
Association between ketamine use and mortality in critically ill patients receiving mechanical ventilation: Analysis of the MIMIC-IV database
Objective: Ketamine, as a sedative, has been administered during mechanical ventilation in critically ill patients; however, its impact on survival outcomes in this patient population remains uncertain. Methods: This retrospective cohort study extracted data from the Medical Information Mart for Intensive Care (MIMIC-IV) database, version 3.0. Patients were categorized into the ketamine group and the control group based on whether ketamine was administered during mechanical ventilation. Propensity score matching was performed to adjust for demographic variables and coexisting conditions. The primary outcome was 28-day mortality. Secondary outcomes included 14-day and 90-day mortality rates, as well as hospital and ICU lengths of stay. Results: The study included a total of 8569 patients, with 330 in the ketamine group and 8239 in the control group. After propensity score matching, significant differences in mechanical ventilation duration and the proportion of patients with acute respiratory distress syndrome remained between groups. No significant differences were observed in 28-day and 90-day mortality rates between the groups. Subgroup analysis indicated that ketamine was associated with lower 14-day mortality rates among younger patients, those with acute respiratory distress syndrome, and norepinephrine users. Ketamine administration was also found to correlate with increased lengths of stay in both the hospital and ICU. Conclusions: Ketamine was more frequently selected for patients requiring prolonged mechanical ventilation. The administration of ketamine was associated with reduced 14-day but not with 28-day or 90-day mortality rates.
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320047
Open AccessAssociation between ketamine use and mortality in critically ill patients receiving mechanical ventilation: Analysis of the MIMIC-IV database
Objective: Ketamine, as a sedative, has been administered during mechanical ventilation in critically ill patients; however, its impact on survival outcomes in this patient population remains uncertain. Methods: This retrospective cohort study extracted data from the Medical Information Mart for Intensive Care (MIMIC-IV) database, version 3.0. Patients were categorized into the ketamine group and the control group based on whether ketamine was administered during mechanical ventilation. Propensity score matching was performed to adjust for demographic variables and coexisting conditions. The primary outcome was 28-day mortality. Secondary outcomes included 14-day and 90-day mortality rates, as well as hospital and ICU lengths of stay. Results: The study included a total of 8569 patients, with 330 in the ketamine group and 8239 in the control group. After propensity score matching, significant differences in mechanical ventilation duration and the proportion of patients with acute respiratory distress syndrome remained between groups. No significant differences were observed in 28-day and 90-day mortality rates between the groups. Subgroup analysis indicated that ketamine was associated with lower 14-day mortality rates among younger patients, those with acute respiratory distress syndrome, and norepinephrine users. Ketamine administration was also found to correlate with increased lengths of stay in both the hospital and ICU. Conclusions: Ketamine was more frequently selected for patients requiring prolonged mechanical ventilation. The administration of ketamine was associated with reduced 14-day but not with 28-day or 90-day mortality rates.
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 3513-3514
The Clinical Considerations of Interscalene Brachial Plexus Block in the Treatment of Post-Hepatectomy Shoulder Pain [Response to Letter]
Response to Letter in regards to Efficacy of Ultrasound-Guided Interscalene Brachial Plexus Block for Acute Post-Hepatectomy Shoulder Pain: A Randomized Controlled Trial [Letter]
- 1 October 2024
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 3513-3514
Open AccessThe Clinical Considerations of Interscalene Brachial Plexus Block in the Treatment of Post-Hepatectomy Shoulder Pain [Response to Letter]
Response to Letter in regards to Efficacy of Ultrasound-Guided Interscalene Brachial Plexus Block for Acute Post-Hepatectomy Shoulder Pain: A Randomized Controlled Trial [Letter]
- Open Access
- 1 September 2024
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 3177-3185
Efficacy of Ultrasound-Guided Interscalene Brachial Plexus Block for Acute Post-Hepatectomy Shoulder Pain: A Randomized Controlled Trial
Objective: To investigate the efficacy of ultrasound-guided interscalene brachial plexus block in the treatment of shoulder pain following hepatectomy. Design: A randomized controlled trial. Methods: We conducted a single-center, randomized controlled trial. Forty-four patients with shoulder pain scores of at least 5 were randomly assigned to two groups: the treatment group, which received 0.5% ropivacaine (5mL) combined with dexamethasone (5 mg) (n=22), and the control group, which received normal saline (5mL) (n=22). The intervention was performed in the postanesthesia care unit after shoulder pain was identified by using the visual analogue scale. The shoulder pain was re-evaluated 15 minutes after intervention. The incidence of effective pain relief, defined as at least 75% reduction in pain intensity, was the primary outcome. Secondary outcomes included shoulder pain intensity within 2 days after surgery, the timing of the first rescue analgesia, total additional analgesic use, arterial oxygen saturation, intervention-related adverse reactions, and patient satisfaction regarding shoulder pain. Results: The incidence of effective pain relief was significantly higher in the treatment group compared to the control group (15 (68.2%) vs 2 (9.1%), P< 0.001). The interscalene brachial plexus block not only prolonged the time to first analgesic request (P < 0.001), but also reduced the number of analgesic requests (P < 0.001). In the comparison between groups, arterial oxygen saturation was lower in the control group than that in the treatment group, attributed to the use of sufentanil for remedial analgesia (92.4% vs 94.5%, P=0.014). Conclusion: Interscalene brachial plexus block can effectively relieve post-hepatectomy shoulder pain without clinically significant hypoxemia.
- 1 September 2024
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 17, 3177-3185
Open AccessEfficacy of Ultrasound-Guided Interscalene Brachial Plexus Block for Acute Post-Hepatectomy Shoulder Pain: A Randomized Controlled Trial
Objective: To investigate the efficacy of ultrasound-guided interscalene brachial plexus block in the treatment of shoulder pain following hepatectomy. Design: A randomized controlled trial. Methods: We conducted a single-center, randomized controlled trial. Forty-four patients with shoulder pain scores of at least 5 were randomly assigned to two groups: the treatment group, which received 0.5% ropivacaine (5mL) combined with dexamethasone (5 mg) (n=22), and the control group, which received normal saline (5mL) (n=22). The intervention was performed in the postanesthesia care unit after shoulder pain was identified by using the visual analogue scale. The shoulder pain was re-evaluated 15 minutes after intervention. The incidence of effective pain relief, defined as at least 75% reduction in pain intensity, was the primary outcome. Secondary outcomes included shoulder pain intensity within 2 days after surgery, the timing of the first rescue analgesia, total additional analgesic use, arterial oxygen saturation, intervention-related adverse reactions, and patient satisfaction regarding shoulder pain. Results: The incidence of effective pain relief was significantly higher in the treatment group compared to the control group (15 (68.2%) vs 2 (9.1%), P< 0.001). The interscalene brachial plexus block not only prolonged the time to first analgesic request (P < 0.001), but also reduced the number of analgesic requests (P < 0.001). In the comparison between groups, arterial oxygen saturation was lower in the control group than that in the treatment group, attributed to the use of sufentanil for remedial analgesia (92.4% vs 94.5%, P=0.014). Conclusion: Interscalene brachial plexus block can effectively relieve post-hepatectomy shoulder pain without clinically significant hypoxemia.
- Open Access
Efficacy of epidural esketamine on postoperative sleep quality after laparoscopic and robotic lower abdominal surgeries: a study protocol for randomised, double-blind, controlled trial
Introduction Postoperative sleep disturbances significantly impair postoperative recovery. The administration of intravenous esketamine has been shown to potentially improve postoperative sleep quality. However, the effectiveness of epidural esketamine in improving postoperative sleep quality remains to be elucidated. This study aims to explore the impact of both intraoperative and postoperative use of epidural esketamine on the postoperative sleep quality of patients undergoing minimally invasive lower abdominal surgeries. Methods and analysis This randomised, double-blind, parallel-group, placebo-controlled trial will be conducted at the Fudan University Shanghai Cancer Centre. A total of 128 adults undergoing minimally invasive lower abdominal surgeries will be randomly allocated in a 1:1 ratio to either the esketamine group or the placebo group. In the esketamine group, epidural esketamine will be administered intraoperatively (0.2 mg/kg) and postoperatively (25 mg). Postoperatively, all patients will receive epidural analgesia. The primary outcome of the study is the incidence of poor sleep quality on the third day after surgery. The sleep quality assessment will be conducted using the Pittsburgh Sleep Quality Index and a Numeric Rating Scale of sleep. The main secondary outcomes include postoperative pain and anxiety and depression scores. The postoperative pain, both rest pain and movement pain, will be assessed using a Numerical Rating Scale within 5 days after surgery. Anxiety and depression scores will be evaluated using the Hospital Anxiety and Depression Scale both before and after the surgery. Safety outcomes will include delirium, fidgeting, hallucinations, dizziness and nightmares. The analyses will be performed in accordance with intention-to-treat principle Ethics and dissemination Ethics approval has been obtained from the Ethics Committee of the Shanghai Cancer Centre (2309281-9). Prior to participation, all patients will provide written informed consent. The results of the trial are intended to be published in a peer-reviewed journal. Trial registration number ChiCTR2300076862.
Open AccessEfficacy of epidural esketamine on postoperative sleep quality after laparoscopic and robotic lower abdominal surgeries: a study protocol for randomised, double-blind, controlled trial
Introduction Postoperative sleep disturbances significantly impair postoperative recovery. The administration of intravenous esketamine has been shown to potentially improve postoperative sleep quality. However, the effectiveness of epidural esketamine in improving postoperative sleep quality remains to be elucidated. This study aims to explore the impact of both intraoperative and postoperative use of epidural esketamine on the postoperative sleep quality of patients undergoing minimally invasive lower abdominal surgeries. Methods and analysis This randomised, double-blind, parallel-group, placebo-controlled trial will be conducted at the Fudan University Shanghai Cancer Centre. A total of 128 adults undergoing minimally invasive lower abdominal surgeries will be randomly allocated in a 1:1 ratio to either the esketamine group or the placebo group. In the esketamine group, epidural esketamine will be administered intraoperatively (0.2 mg/kg) and postoperatively (25 mg). Postoperatively, all patients will receive epidural analgesia. The primary outcome of the study is the incidence of poor sleep quality on the third day after surgery. The sleep quality assessment will be conducted using the Pittsburgh Sleep Quality Index and a Numeric Rating Scale of sleep. The main secondary outcomes include postoperative pain and anxiety and depression scores. The postoperative pain, both rest pain and movement pain, will be assessed using a Numerical Rating Scale within 5 days after surgery. Anxiety and depression scores will be evaluated using the Hospital Anxiety and Depression Scale both before and after the surgery. Safety outcomes will include delirium, fidgeting, hallucinations, dizziness and nightmares. The analyses will be performed in accordance with intention-to-treat principle Ethics and dissemination Ethics approval has been obtained from the Ethics Committee of the Shanghai Cancer Centre (2309281-9). Prior to participation, all patients will provide written informed consent. The results of the trial are intended to be published in a peer-reviewed journal. Trial registration number ChiCTR2300076862.
- Open Access
- 21 December 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (12) , e0296158
Anesthesia-related intervention for long-term survival and cancer recurrence following breast cancer surgery: A systematic review of prospective studies
Objective: Anesthesia is correlated with the prognosis of cancer surgery. However, evidence from prospective studies focusing on breast cancer is currently limited. This systematic review aimed to investigate the effect of anesthesia-related interventions on oncological outcomes following breast cancer surgery in prospective studies. Methods: Literature searches were performed from inception to June. 2023 in the Pubmed, Web of Science, Embase, and ClinicalTrials databases. The main inclusion criteria comprised a minimum of one-year follow-up duration, with oncological outcomes as endpoints. Anesthesia-related interventions encompassed, but were not limited to, type of anesthesia, anesthetics, and analgesics. The risk of bias was assessed using the Cochrane Risk of Bias Tool. Results: A total of 9 studies were included. Anesthesia-related interventions included paravertebral nerve block (3), pectoral nerve block (1), sevoflurane (2), ketorolac (2), and infiltration of lidocaine (1). Cancer recurrence, metastasis, disease-free survival, or (and) overall survival were assessed. Among all included studies, only infiltration of lidocaine was found to prolong disease-free survival and overall survival. Conclusion: Regional anesthesia and propofol did not improve oncological outcomes following breast cancer surgery. The anti-tumorigenic effect of ketorolac warrants future studies with larger sample sizes. Perioperative infiltration of lidocaine around the tumor may be a promising anti-tumorigenic intervention that can prolong overall survival in patients with early breast cancer.
- 21 December 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (12) , e0296158
Open AccessAnesthesia-related intervention for long-term survival and cancer recurrence following breast cancer surgery: A systematic review of prospective studies
Objective: Anesthesia is correlated with the prognosis of cancer surgery. However, evidence from prospective studies focusing on breast cancer is currently limited. This systematic review aimed to investigate the effect of anesthesia-related interventions on oncological outcomes following breast cancer surgery in prospective studies. Methods: Literature searches were performed from inception to June. 2023 in the Pubmed, Web of Science, Embase, and ClinicalTrials databases. The main inclusion criteria comprised a minimum of one-year follow-up duration, with oncological outcomes as endpoints. Anesthesia-related interventions encompassed, but were not limited to, type of anesthesia, anesthetics, and analgesics. The risk of bias was assessed using the Cochrane Risk of Bias Tool. Results: A total of 9 studies were included. Anesthesia-related interventions included paravertebral nerve block (3), pectoral nerve block (1), sevoflurane (2), ketorolac (2), and infiltration of lidocaine (1). Cancer recurrence, metastasis, disease-free survival, or (and) overall survival were assessed. Among all included studies, only infiltration of lidocaine was found to prolong disease-free survival and overall survival. Conclusion: Regional anesthesia and propofol did not improve oncological outcomes following breast cancer surgery. The anti-tumorigenic effect of ketorolac warrants future studies with larger sample sizes. Perioperative infiltration of lidocaine around the tumor may be a promising anti-tumorigenic intervention that can prolong overall survival in patients with early breast cancer.
- Open Access
- 1 January 2015
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2015, 1-7
Efficacy of Pulsed Radiofrequency on Cervical 2-3 Posterior Medial Branches in Treating Chronic Migraine: A Randomized, Controlled, and Double-Blind Trial
Objective. The aim of this study was to examine the efficacy and safety of pulsed radiofrequency (PRF) in the treatment of chronic migraine (CM) on cervical 2-3 posterior medial branches.Methods. This randomized, double-blind, and controlled clinical trial included 40 subjects with CM, who were randomly divided into two groups: treatment (treated by PRF) and sham (treated by sham treatment). Pain intensity, headache duration (days), the Migraine Disability Assessment Questionnaire (MIDAS), and aspirin dose taken by patients were evaluated at 1, 2, and 6 months after the intervention. Side effects were observed from the time of treatment and throughout the follow-up period.Results. During the follow-up, pain intensity, headache duration (days), disability score, and the analgesic dose were significantly improved in the treatment group compared to the sham group () and the baseline () at all measured time points after intervention. No serious complications were reported.Conclusion. PRF on the cervical 2-3 posterior medial branches could provide satisfactory efficacy in the treatment of CM without obvious adverse effects.- 1 January 2015
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2015, 1-7
Open AccessEfficacy of Pulsed Radiofrequency on Cervical 2-3 Posterior Medial Branches in Treating Chronic Migraine: A Randomized, Controlled, and Double-Blind Trial
Objective. The aim of this study was to examine the efficacy and safety of pulsed radiofrequency (PRF) in the treatment of chronic migraine (CM) on cervical 2-3 posterior medial branches.Methods. This randomized, double-blind, and controlled clinical trial included 40 subjects with CM, who were randomly divided into two groups: treatment (treated by PRF) and sham (treated by sham treatment). Pain intensity, headache duration (days), the Migraine Disability Assessment Questionnaire (MIDAS), and aspirin dose taken by patients were evaluated at 1, 2, and 6 months after the intervention. Side effects were observed from the time of treatment and throughout the follow-up period.Results. During the follow-up, pain intensity, headache duration (days), disability score, and the analgesic dose were significantly improved in the treatment group compared to the sham group () and the baseline () at all measured time points after intervention. No serious complications were reported.Conclusion. PRF on the cervical 2-3 posterior medial branches could provide satisfactory efficacy in the treatment of CM without obvious adverse effects.